GSK

GSK’s annual Palio meeting is taking place with a focus on how preventative approaches to disease can help mitigate climate change.  GSK’s ‘Vaccines for a sustainable planet’ meeting is gathering 65 experts across immunology, vaccinology, epidemiology, and policy throughout 7-8 July.  The meeting will include a range of plenary sessions and working group discussions that […]

GSK has completed its acquisition of the biopharmaceutical company Sierra Oncology, boosting its portfolio of oncology medicines.  The deal was announced back in April this year and sees GSK acquiring Sierra Oncology for a total of $1.9 billion. The acquisition will give GSK access to Sierra’s late-stage candidate momelotinib, which is being developed to treat […]

Drug Discovery World Editor Reece Armstrong looks at how a number of deals in pharma have sparked excitement in the industry.  A number of recently announced deals by pharma companies has brought some excitement back into the sector after a rather stagnant period of activity.   At the start of June, GSK announced it would be […]

GSK is to invest £1 billion over the course of 10 years into research on infectious diseases that largely affect low-income countries.   In particular, the pharmaceutical company will aim to develop new vaccines and medicines that prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR) – all […]

GSK’s vaccine for the prevention of measles, mumps and rubella (MMR) has been approved by the US FDA, the company has announced.  The approval of GSK’s Priorix in the US gives patients another option for being vaccinated against MMR. The vaccine is already licensed in over 100 countries and more than 800 million doses have been […]

GSK will acquire clinical-stage biopharmaceutical company Affinivax in a deal potentially worth over $3 billion.  GSK will acquire Affinivax for an upfront payment of $2.1 billion and is offering up to $1.2 billion in potential development milestones.   Affinivax is developing a novel class of vaccines, its most advanced of which is focused on pneumococcal diseases. […]

News round-up by DDW’s Reece Armstrong for 25-29 April     Q1 earnings, formulations to tackle blindness, liver cancer therapies and opportunities for malaria treatments are some of the themes of this week’s news round-up.  What’s behind GSK’s strong Q1 earnings?  DDW Deputy Editor Reece Armstrong looks at the key points of GSK’s first quarter earnings. UK […]

DDW Deputy Editor Reece Armstrong looks at the key points of GSK’s first quarter earnings.   UK pharmaceutical company GSK has reported strong financial earnings for the first quarter of 2022.  The pharma giant reported total sales in Q1 of £9.8 billion, crediting much of that to the company’s biopharma offerings.  In a breakdown of GSK’s […]